Luminex® xMAP® technology is an effective strategy for high-definition human leukocyte antigen typing of cord blood units prior to listing

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Allele-level donor–recipient match at HLA-A, HLA-B, HLA-C and HLA-DRB1 loci impacts the outcome after cord blood transplantation for hematologic malignancies and modifies the strategy of donor selection. High definition of both class I and II HLA loci at time of listing is a way to improve the attractiveness of cord blood bank inventories, reducing the time for donor search and procurement and simplifying donor choice, in particular, for patients of non-European heritage. Methods: In 2014, Luminex® xMAP® technology was introduced in our laboratory practice and was applied to cord blood units typing. In this study, we evaluated the impact of this strategy in comparison with the platform in use until 2013, relying on LiPA reverse polymerase chain reaction–sequence-specific oligonucleotide (revPCR-SSO) plus polymerase chain reaction–sequence-specific primer (PCR-SSP). Results: In 2014, the time for testing was shorter (141 vs 181 days on average), the number of test repetitions was lower (in particular for HLA-A locus, p = 0.026), and the cost reduced (240.7 vs 395.6 euros per unit on average) compared to 2013, demonstrating that Luminex xMAP technology is superior to the previous approach. Conclusion: Luminex xMAP platform has useful application in cord blood banking programs, to achieve high-definition HLA typing of cord blood units at the time of banking in a quick, accurate, and cost-effective manner.

Original languageEnglish
JournalInternational Journal of Artificial Organs
DOIs
Publication statusAccepted/In press - Mar 1 2018

Fingerprint

Antigens
HLA Antigens
Fetal Blood
Blood
Technology
Blood Banks
HLA-A Antigens
Tissue Donors
Blood Grouping and Crossmatching
HLA-C Antigens
HLA-DRB1 Chains
Costs and Cost Analysis
Donor Selection
Histocompatibility Testing
HLA-B Antigens
Oligonucleotides
Hematologic Neoplasms
Costs
Transplantation
Alleles

Keywords

  • Cord blood
  • human leukocyte antigen typing
  • Luminex xMAP technology

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomaterials
  • Biomedical Engineering

Cite this

@article{2981c4581ff549cbb9f9ce8500475e31,
title = "Luminex{\circledR} xMAP{\circledR} technology is an effective strategy for high-definition human leukocyte antigen typing of cord blood units prior to listing",
abstract = "Introduction: Allele-level donor–recipient match at HLA-A, HLA-B, HLA-C and HLA-DRB1 loci impacts the outcome after cord blood transplantation for hematologic malignancies and modifies the strategy of donor selection. High definition of both class I and II HLA loci at time of listing is a way to improve the attractiveness of cord blood bank inventories, reducing the time for donor search and procurement and simplifying donor choice, in particular, for patients of non-European heritage. Methods: In 2014, Luminex{\circledR} xMAP{\circledR} technology was introduced in our laboratory practice and was applied to cord blood units typing. In this study, we evaluated the impact of this strategy in comparison with the platform in use until 2013, relying on LiPA reverse polymerase chain reaction–sequence-specific oligonucleotide (revPCR-SSO) plus polymerase chain reaction–sequence-specific primer (PCR-SSP). Results: In 2014, the time for testing was shorter (141 vs 181 days on average), the number of test repetitions was lower (in particular for HLA-A locus, p = 0.026), and the cost reduced (240.7 vs 395.6 euros per unit on average) compared to 2013, demonstrating that Luminex xMAP technology is superior to the previous approach. Conclusion: Luminex xMAP platform has useful application in cord blood banking programs, to achieve high-definition HLA typing of cord blood units at the time of banking in a quick, accurate, and cost-effective manner.",
keywords = "Cord blood, human leukocyte antigen typing, Luminex xMAP technology",
author = "Marco Guarene and Carla Badulli and Cremaschi, {Anna L.} and Ilaria Sbarsi and Rosalia Cacciatore and Carmine Tinelli and Annamaria Pasi and Paola Bergamaschi and Perotti, {Cesare G.}",
year = "2018",
month = "3",
day = "1",
doi = "10.1177/0391398818762356",
language = "English",
journal = "International Journal of Artificial Organs",
issn = "0391-3988",
publisher = "Wichtig Publishing",

}

TY - JOUR

T1 - Luminex® xMAP® technology is an effective strategy for high-definition human leukocyte antigen typing of cord blood units prior to listing

AU - Guarene, Marco

AU - Badulli, Carla

AU - Cremaschi, Anna L.

AU - Sbarsi, Ilaria

AU - Cacciatore, Rosalia

AU - Tinelli, Carmine

AU - Pasi, Annamaria

AU - Bergamaschi, Paola

AU - Perotti, Cesare G.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Introduction: Allele-level donor–recipient match at HLA-A, HLA-B, HLA-C and HLA-DRB1 loci impacts the outcome after cord blood transplantation for hematologic malignancies and modifies the strategy of donor selection. High definition of both class I and II HLA loci at time of listing is a way to improve the attractiveness of cord blood bank inventories, reducing the time for donor search and procurement and simplifying donor choice, in particular, for patients of non-European heritage. Methods: In 2014, Luminex® xMAP® technology was introduced in our laboratory practice and was applied to cord blood units typing. In this study, we evaluated the impact of this strategy in comparison with the platform in use until 2013, relying on LiPA reverse polymerase chain reaction–sequence-specific oligonucleotide (revPCR-SSO) plus polymerase chain reaction–sequence-specific primer (PCR-SSP). Results: In 2014, the time for testing was shorter (141 vs 181 days on average), the number of test repetitions was lower (in particular for HLA-A locus, p = 0.026), and the cost reduced (240.7 vs 395.6 euros per unit on average) compared to 2013, demonstrating that Luminex xMAP technology is superior to the previous approach. Conclusion: Luminex xMAP platform has useful application in cord blood banking programs, to achieve high-definition HLA typing of cord blood units at the time of banking in a quick, accurate, and cost-effective manner.

AB - Introduction: Allele-level donor–recipient match at HLA-A, HLA-B, HLA-C and HLA-DRB1 loci impacts the outcome after cord blood transplantation for hematologic malignancies and modifies the strategy of donor selection. High definition of both class I and II HLA loci at time of listing is a way to improve the attractiveness of cord blood bank inventories, reducing the time for donor search and procurement and simplifying donor choice, in particular, for patients of non-European heritage. Methods: In 2014, Luminex® xMAP® technology was introduced in our laboratory practice and was applied to cord blood units typing. In this study, we evaluated the impact of this strategy in comparison with the platform in use until 2013, relying on LiPA reverse polymerase chain reaction–sequence-specific oligonucleotide (revPCR-SSO) plus polymerase chain reaction–sequence-specific primer (PCR-SSP). Results: In 2014, the time for testing was shorter (141 vs 181 days on average), the number of test repetitions was lower (in particular for HLA-A locus, p = 0.026), and the cost reduced (240.7 vs 395.6 euros per unit on average) compared to 2013, demonstrating that Luminex xMAP technology is superior to the previous approach. Conclusion: Luminex xMAP platform has useful application in cord blood banking programs, to achieve high-definition HLA typing of cord blood units at the time of banking in a quick, accurate, and cost-effective manner.

KW - Cord blood

KW - human leukocyte antigen typing

KW - Luminex xMAP technology

UR - http://www.scopus.com/inward/record.url?scp=85045084250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045084250&partnerID=8YFLogxK

U2 - 10.1177/0391398818762356

DO - 10.1177/0391398818762356

M3 - Article

AN - SCOPUS:85045084250

JO - International Journal of Artificial Organs

JF - International Journal of Artificial Organs

SN - 0391-3988

ER -